Injective just rang the opening bell at @Nasdaq. Injective’s CEO, @ericinjective, alongside Canary’s CEO, @StevenMcClurg, officially launched the market, commemorating the debut of $INJC—the first U.S.-listed ETF staking Injective-protocol:native tokens. From a dorm room in 2018 to the heart of Wall Street. There’s much more ahead. What is $INJC and why does it matter? The Canary Staked INJ ETF (ticker: INJC) began trading on Nasdaq on November 5, 2026. It is the first U.S. ETF to hold actual spot Injective-protocol:native tokens, staking at least 90% of those tokens. Staking rewards are reinvested into the fund, meaning each INJC share gradually represents more Injective-protocol:native tokens over time. No cash dividends are paid—you simply sell shares to exit, without waiting 21 days for unstaking. What does this mean for newcomers? Previously, owning and staking Injective-protocol:native required setting up your own wallet, selecting a validator, and managing private keys—a barrier for many investors, financial advisors, and institutions. INJC combines both functions into a single ticker, purchasable in USD through a standard brokerage account. Injective was once just a blockchain built for finance. Now, Injective-protocol:native is among a very small group of crypto assets with a spot ETF in the U.S.—joining Bitcoin, Ethereum, Solana, XRP, Chainlink, and others. Compared to holding Injective-protocol:native directly: - INJC: Simple, no wallet needed, trades during U.S. market hours, suitable for retirement accounts - Injective-protocol:native token: Vote on governance, use on-chain apps, participate in BuyBacks, trade 24/7 INJC is not just a new financial product—it’s a major milestone that officially brings Injective from a specialized on-chain finance blockchain into the mainstream U.S. financial system.